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Abstract
Background: Tumor-associated macrophages (TAMs) play an important role in growth, progression and metastasis
of tumors. In non-small cell lung cancer (NSCLC), TAMs’ anti-tumor or pro-tumor role is not determined.
Macrophages are polarized into M1 (with anti-tumor function) and M2 (with pro-tumor function) forms. This study
was conducted to determine whether the M1 and M2 macrophage densities in NSCLC are associated with
patient’s survival time.
Methods: Fifty patients with an average of 1-year survival (short survival group) and 50 patients with an average of
5-year survival (long survival group) were included in this retrospective study. Paraffin-embedded NSCLC specimens
and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical
double-staining of CD68/HLA-DR (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages)
was performed and evaluated in a blinded fashion. The M1 and M2 macrophage densities in the tumor islets,
stroma, or islets and stroma were determined using computer-aided microscopy. Correlation of the macrophage
densities and patient’s survival time was analyzed using the Statistical Package for the Social Sciences.
Results: Approximately 70% of TAMs were M2 macrophages and the remaining 30% were M1 macrophages in
NSCLC. The M2 macrophage densities (approximately 78 to 113 per mm2) in the tumor islets, stroma, or islets and
stroma were not significantly different between the long survival and short survival groups. The M1 macrophage
densities in the tumor islets (approximately 70/mm2) and stroma (approximately 34/mm2) of the long survival
group were significantly higher than the M1 macrophage densities in the tumor islets (approximately 7/mm2) and
stroma (13/mm2) of the short survival group (P < 0.001 and P < 0.05, respectively). The M2 macrophage densities
were not associated with patient’s survival time. The M1 macrophage densities in the tumor islets, stroma, or islets
and stroma were positively associated with patient’s survival time in a univariate analysis (P < 0.01 or 0.001). In a
multivariate Cox proportional hazards analysis, the M1 macrophage density in the tumor islets was an independent
predictor of patient’s survival time.
Conclusions: The M1 macrophage density in the tumor islets is an independent predictor of survival time in
NSCLC patients.
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Background
Non-small cell lung cancer (NSCLC) remains the most
common cause of cancer-related death worldwide.
Metastasis may have occurred at the time of initial diag-
nosis, even at a very early stage such as stage IA. That
explains why the five-year survival rate is approximately
67% for patients with stage IA NSCLC after putatively
curative surgical resection [1]. Tumor cells use multiple
mechanisms to invade extracellular matrix and metasta-
size to distant organs. The interaction between the
tumor cells and stromal cells in the tumor microenvir-
onment plays an important role in tumor growth and
metastasis. Macrophages are prominent stromal cells in
this interaction. They secret a variety of growth factors,
cytokines, chemokines, and enzymes that regulate tumor
growth, angiogenesis, invasion, and metastasis [2].
Recently, it has been well recognized that tumor-asso-
ciated macrophages (TAMs) are not homogenous [3].
Microlocalization, in terms of where macrophages are
observed under a microscope, is an important factor for
prognosis. Increased number of macrophages within the
tumor islets confers a marked survival advantage, whereas
increased number of macrophages in the tumor stroma is
associated with poor prognosis in NSCLC [4]. In addition,
macrophages are polarized into two functionally distinct
forms M1 and M2, mirroring the Th1 and Th2 nomencla-
ture of T cells [3]. Differentiation of the M1 macrophages
is induced by interferon-g, lipopolysaccharides, tumor
necrosis factor (TNF) a, and granulocyte-monocyte col-
ony-stimulating factor. The M1 macrophages produce
high levels of interleukin (IL)-12, IL-23, TNFa, IL-1, IL-6,
CXC ligand 10 (CXCL10), inducible nitric oxide synthase
(iNOS), human leukocyte antigen (HLA)-DR, and reactive
oxygen and nitrogen intermediates [3,5-7]. Differentiation
of the M2 macrophages is induced by IL-4, IL-10, IL-13,
IL-21, activin A, immune complexes, and glucocorticoid
[3]. The M2 macrophages express high levels of IL-10, IL-
1 receptor antagonist, CC ligand 22 (CCL22), scavenger,
mannose receptor, galactose receptor, arginase I, and
CD163 antigen [3,8]. Ohri et al recently reported that the
M1 macrophage density in the tumor islets is positively
associated with extended survival of NSCLC patients [9].
We have previously reported that the number of
TAMs in the tumor islets and the ratio of TAMs in the
tumor islets versus stroma are positively associated with
survival time in patients with NSCLC [10]. In this study,
we further determined that the M1 form of TAMs is an
independent prognostic factor in patients with NSCLC.
Methods
Study population
This study was approved by the Institutional Review
Board of West China Hospital, Sichuan University. The
procedures to obtain human lung cancer tissues and fol-
low-up information are in accordance with the Ethical
Principles for Medical Research Involving Human Sub-
jects as formulated in the World Medical Association
Declaration of Helsinki (revised in 2008). All specimens
were obtained from the archives of formalin-fixed, paraf-
fin-embedded tissue blocks in the Department of Thor-
acic and Cardiovascular Surgery, West China Hospital,
Sichuan University. The lung cancer tissues were col-
lected from surgeries performed from June, 1999 to
August, 2001. The patients were followed up until
December, 2007, through outpatient visits and/or corre-
spondences to family members. Fifty patients with long
survival time (1972.0 ± 78.0 days) and 50 patients with
short survival time (351.8 ± 32.5 days) were included in
this retrospective study. The inclusion criteria were: (1)
follow-up data were complete; and (2) paraffin blocks
were available; and (3) without pre-operative chemother-
apy or radiotherapy. All of the cases that satisfied the
inclusion criteria were included in this study. Histologi-
cal evaluation was based on the World Health Organiza-
tion criteria. Tumor stage was evaluated according to
the International Union against Cancer TNM classifica-
tion system. The clinicopathological characteristics were
summarized in Table 1.
Immunohistochemistry
Four-μm thick tissue sections were de-waxed in xylene
and rehydrated through graded alcohols. Antigen retrie-
val was carried out using microwave at middle-to-high
temperature for 8 min, low-to-high temperature for 5
min, and then cooled down at room temperature for 20
min. Mouse anti-human CD68 monoclonal antibodies
(clone KP1, recognizing macrophages), mouse anti-
HLA-DR monoclonal antibodies (clone LN3, recognizing
M1 macrophages), and mouse anti-human CD163 anti-
gen monoclonal antibodies (clone 10D6, recognizing M2
macrophages) were produced by Invitrogen, Carlsbad,
CA, and were obtained from Zhongshan Goldenbridge
Biotechnology Co., LTD., Beijing, China. Mouse IgG1
(clone NCG01, Abcam, Cambridge, MA, USA) was used
as an isotype negative control.
Immunohistochemical staining of individual marker or
double-staining of CD68 and CD163 or CD68 and
HLA-DR was performed using the DouSP™ double-stain
kit (Maxim-Bio, Fuzhou City, Fujian Province, China)
according to the manufacturer’s instructions. Develop-
ment of red color was performed using streptavidin-per-
oxidase conjugate and 3-Amino-9-ethylcarbazole (AEC).
Development of black-purple color was performed using
streptavidin-alkaline-phosphatase conjugate and 5-
bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue
tetrazolium (NBT). Sections were then counterstained
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with hematoxylin and mounted in an aqueous mounting
medium. Tissue sections with macrophages previously
stained positively were used as positive control, while
tissue sections with primary antibodies replaced by
mouse isotype IgG1 served as negative control. Five
representative high-power fields (× 400 magnification)
per tissue section were selected using an Olympus BX51
microscope (Olympus, Tokyo, Japan). Areas of the
tumor islets, tumor stroma, or combination of the
tumor islets and stroma were defined and measured
using the Image-Pro Plus 6.0 software (Media Cyber-
netics, Silver Spring, MD, USA). The number of
nucleated cells with positive staining for the phenotypic
marker in each area was counted. Macrophage density
was calculated as cell number per mm2 of the tumor
islets, stroma, or islets and stroma. Evaluation of the
stained tissue sections was performed by two investiga-
tors who were blinded in regard to which group the
specimens belonged to. Macrophage density of each
case was an average of the results obtained by the two
examiners.
Statistical analysis
Statistical analysis was carried out using the Statistical
Package for the Social Sciences (SPSS, version 13.0,
SPSS Inc., Chicago, IL, USA). For categorical analysis,
the median value of macrophage density was used as a
cut-off point to dichotomize the continuous variables.
The Mann-Whitney nonparametric test was used to
compare between two groups. The Spearman’s rank cor-
relation coefficient was calculated to assess any potential
relationship between macrophage density and patient’s
survival time. The Kaplan-Meier survival curves were
used to look for correlation between macrophage den-
sity and patient’s survival time. Statistical significance
was analyzed using the log-rank test. A multivariate Cox
proportional hazards model was used to estimate
adjusted hazard ratios and 95% confidence intervals (CI)
and to identify which form of macrophages was an inde-
pendent prognostic factor. The validity of the propor-
tional hazards assumption was assessed from log (-log
[Survival]) curves. For the above comparisons, P < 0.05
was considered statistically significant.
Results
Patient characteristics
Among the 100 patients (Table 1) who had undergone
surgery, 10 patients received additional chemotherapy
after surgery. No patients received radiotherapy before
or after surgery. All of the patients had complete fol-
low-up information and the pathological diagnosis was
verified by a pathologist prior to inclusion in this study.
The overall cumulative survival rates were 68% for 1
year, 46% for 3 years, and 32% for 5 years. The group
of patients with long survival time had survived 5.4
years on the average, whereas the group of patients
with short survival time had lived only about one year
(Table 1).
Table 1 Clinicopathological characteristics of patients with non-small cell lung cancer (n = 100)
Variable Long survival (n = 50) Short survival (n = 50)
Survival (days, mean ± standard error) 1972.0 ± 78.0 351.8 ± 32.5
Age (years, mean ± standard error) 58.0 ± 1.4 60.5 ± 1.3
Gender (male: female) 40:10 41:9
Tumor stage: number (%)
I 24 (48) 11 (22)
II 9 (18) 11 (22)
III 15 (30) 20 (40)
IV 2 (4) 8 (16)
Histology: number (%)
Adenocarcinoma 12 (24) 24 (48)
Squamous 34 (68) 17 (34)
Alveolar cell 3 (6) 7 (14)
Large cell 1 (2) 2 (4)
Tumor grade: number (%)
Well differentiation 2 (4) 0 (0)
Moderate differentiation 27 (54) 21 (42)
Poor differentiation 15 (30) 15 (30)
Not recorded 6 (12) 14 (28)
Lymph node metastasis: number (%)
No 37 (74) 23 (46)
Yes 13 (26) 27 (54)
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Immunohistochemical detection of macrophages
In order to assess whether the markers chosen actually
detect different cellular subsets of macrophages, tissue
sections from five patients were initially stained for
CD68, CD163, or HLA-DR, alone or in combination. It
was found that CD68 staining identified cells with mor-
phological features of macrophages. Among the CD68+
macrophages, some of them stained positively for HLA-
DR, a marker of the M1 macrophages (Figure 1a),
whereas others stained positively for CD163, a marker
of the M2 macrophages (Figure 1b). In double-staining
for CD163 and HLA-DR, a majority of macrophages
stained positively for either CD163 or HLA-DR (Figure
1c). Only a small percentage of macrophages (median
3.1%, range 1.2% - 8.1%) stained positively for both
CD163 and HLA-DR.
M1 and M2 macrophage densities in the tumor islets and
stroma
When the M1 and M2 macrophages on the tumor sec-
tions (including the tumor islets and stroma) were
counted under high-power fields, approximately 70% of
macrophages were CD68+/CD163+ M2 macrophages
and the remaining 30% of them were CD68+/HLA-DR+
M1 macrophages. The M1 macrophage density
(approximately 70/mm2) in the tumor islets and stroma
of patients with long survival time was significantly
higher (about 4 times) than the M1 macrophage density
(approximately 17/mm2) in the tumor islets and stroma
of patients with short survival time (P < 0.001)
(Table 2). The M2 macrophage density in the tumor
islets and stroma of the long survival group (approxi-
mately 98/mm2) was not significantly different from the
M2 macrophage density in the tumor islets and stroma
of the short survival group (approximately 110/mm2)
(P > 0.05). The M1/M2 ratio in the tumor islets and
stroma was 0.7 in patients with long survival time and
0.2 in patients with short survival time (Table 2).
When the M1 and M2 macrophages were assessed in the
tumor islets or stroma individually, the M1 macrophage
densities in the tumor islets (approximately 70/mm2) and
stroma (approximately 34/mm2) of the long survival group
were significantly higher than the M1 macrophage densi-
ties in the tumor islets (approximately 7/mm2) and stroma
Figure 1 Immunohistochemical detection of macrophages in NSCLC tumor islets. a) The M1 macrophage double stained with the anti-
CD68 (red) and anti-HLA-DR (black-purple) antibodies (arrow). b) The M2 macrophages double stained with the anti-CD68 (red) and anti-CD163
(black-purple) antibodies (arrow). c) The M1 macrophage marker HLA-DR stained black-purple (arrowhead) and the M2 macrophage marker
CD163 stained red (arrow). Original magnification, × 1000 for a & b, and × 400 for c.
Table 2 Density and microlocalization of macrophages in non-small cell lung cancer
Long survival Short survival [I +S] long/
MF Form Islets Stroma I + S Islets Stroma I + S [I + S] short
M1 70.1 (0 - 255.3) 33.6 (0 - 257.1) 70.4 (0 - 255.7) 7.3 (0 - 74.9) 13.1 (0 - 129.9) 17.2 (0 - 132.2) 4.1
M2 77.6 (0 - 356.9) 78.4 (0 - 327.9) 97.9 (0 - 299.2) 113.4 (0 - 311.5) 79.5 (0 - 234.3) 109.5 (0 - 257.5) 0.9
M1/M2 0.9 0.4 0.7 0.1 0.2 0.2 4.5
Macrophage (MF) density is presented as median (range) of cell number per mm2. I +S represents median (range) of the macrophage density in the tumor islets
and stroma, which is obtained based on macrophage number per mm2 of the tumor sections and not a simple sum of the macrophage densities in the islets
plus that in the stroma. [I +S] long/[I +S] short represents a ratio of the median macrophage density in the tumor islets and stroma of the long survival group
versus that of the short survival group. Analyzed with Mann-Whitney nonparametric test, the M1 macrophage densities in the tumor islets, stroma, and I+S of
patients with long survival time are significantly higher than those of patients with short survival time (P < 0.001, P < 0.05, and P < 0.001, respectively). The M2
macrophage densities in the tumor islets, stroma, and I+S of patients with long survival time are not significantly different from those of patients with short
survival time (P = 0.526, P = 0.929, and P = 0.329, respectively). The M2 macrophage density is not significantly different from the M1 macrophage density in the
tumor islets of patients with long survival time (P > 0.05). The M2 macrophage density in the tumor stroma of the long survival group and the M2 macrophage
densities in the tumor islets or stroma of the short survival group are significantly higher than the corresponding M1 macrophage densities (P < 0.01).
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(13/mm2) of the short survival group (P < 0.001 and
P < 0.05, respectively) (Table 2). The M2 macrophage
densities in the tumor islets (approximately 78/mm2) and
stroma (approximately 78/mm2) of the long survival group
were not significantly different from the M2 macrophage
densities in the tumor islets (approximately 113/mm2) and
stroma (80/mm2) of the short survival group (P > 0.05)
(Table 2). The M1/M2 ratios in the tumor islets (a ratio of
0.9) and stroma (a ratio of 0.4) of patients with long survi-
val time were about 9 and 2 times of the corresponding
M1/M2 ratios in the tumor islets (a ratio of 0.1) and
stroma (a ratio of 0.2) of patients with short survival time,
respectively (Table 2).
Correlation between the macrophage density and survival
time
Scatter plots of the macrophage density versus survival
time were shown in Figure 2. The Spearman’s rank cor-
relation coefficient (rs) was calculated to assess any
potential relationship between the macrophage density
and patient’s survival time. We found that the M1
macrophage densities in the tumor islets, stroma, or
islets and stroma were positively associated with
patient’s survival time, with rs = 0.745 (P < 0.001),
0.271 (P < 0.01), and 0.544 (P < 0.001), respectively.
In contrast, there was no association between the M2
macrophage densities and patient’s survival time
(P > 0.05).
In order to assess whether there is any value of the
macrophage density in predicting prognosis, the median
value of the macrophage density was used as a cut-off
point to dichotomize the 100 patients into a group with
a macrophage density above the median and a group
with a macrophage density below the median. We found
that patients with above-the-median M1 macrophage
density in the tumor islets had a 1-year survival rate of
94%, 3-year survival rate of 74%, and 5-year survival rate
of 54%, which were significantly higher than the corre-
sponding survival rates (42%, 18%, and 10%, respectively,
P < 0.001) in patients with below-the-median M1
macrophage density in the tumor islets (Table 3).
Patients with above-the-median M1 macrophage density
in the tumor stroma had a 1-year survival rate of 78%,
3-year survival rate of 58%, and 5-year survival rate of
42%, which were significantly higher than the corre-
sponding survival rates (58%, 34%, and 22%, respectively,
P < 0.01) in patients with below-the-median M1 macro-
phage density in the tumor stroma. Patients with above-
the-median M1 macrophage density in the tumor islets
and stroma had a 1-year survival rate of 90%, 3-year
Figure 2 Scatter plots of the macrophage density versus patient’s survival time. rs represents the Spearman’s rank correlation coefficient.
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survival rate of 70%, and 5-year survival rate of 50%,
which were significantly higher than the corresponding
survival rates (46%, 22%, and 14%, respectively, P <
0.001) in patients with below-the-median M1 macro-
phage density in the tumor islets and stroma (Table 3).
In contrast, the M2 macrophage densities in the tumor
islets, stroma, or islets and stroma had no statistically
significant association with patient’s survival time. The
Kaplan-Meier survival curves further illustrated associa-
tion of the M1 but not M2 macrophage densities with
patient’s survival time (Figure 3).
In order to determine whether the macrophage den-
sity is independently associated with patient’s survival
time, the multivariate Cox proportional hazards analysis
was used. Tumor stage, histology and grade were
included in the multivariate analysis along with the
macrophage density, because we found that there was
no statistically significant association between the M1
macrophage density and these clinicopathological char-
acteristics (P > 0.05). Status of lymph node metastasis
was excluded because the patients with lymph node
metastasis had statistically lower M1 macrophage den-
sity in the tumor islets than the patients without lymph
node metastasis (P < 0.05). We found that the M1
macrophage density in the tumor islets was a positive
independent predictor of patient’s survival time (hazard
ratio 0.982, 95% CI 0.975 - 0.989, P < 0.001). The M1
macrophage densities in the tumor stroma or tumor
islets and stroma, or any M2 macrophage densities had
no statistically significant association with patient’s sur-
vival time in the multivariate analysis (Table 3).
Discussion
Macrophage is a major component of inflammatory
infiltrate of tumors [11,12]. Tumor-associated macro-
phages (TAMs) have complex dual functions in terms of
their anti-tumor or pro-tumor effects. This functional
complexity is related to the heterogeneity of macro-
phage population that hold a continuum of diverse func-
tional states. At one end of the continuum are the
classically activated M1 macrophages that produce effec-
tor molecules such as reactive oxygen intermediates,
reactive nitrogen intermediates, and TNFa, to limit
tumor growth. At the other end are the alternatively
activated M2 macrophages that promote tumor growth
and metastasis by secretion of matrix-degrading
enzymes, angiogenic factors and immunosuppressive
cytokines/chemokines [5]. The balance of these
Table 3 Correlation between the density and microlocalization of macrophages and survival time in non-small cell
lung cancer patients
Survival rate (%) P
(univariate)
Cox regression
Density and microlocalization n 1-yr 3-yr 5-yr Hazard ratio (95% CI) P
(multivariate)
M1 density in islets 0.982
(0.975 - 0.989)
< 0.001
Above median 50 94 74 54 < 0.001
Below median 50 42 18 10
M1 density in stroma 1.001
(0.992 - 1.009)
0.889
Above median 50 78 58 42 0.009
Below median 50 58 34 22
M1 density in islets + stroma 1.001
(0.986 - 1.015)
0.943
Above median 50 90 70 50 < 0.001
Below median 50 46 22 14
M2 density in islets 0.997
(0.989 - 1.006)
0.535
Above median 50 68 38 28 0.288
Below median 50 68 54 36
M2 density in stroma 0.997
(0.991 - 1.004)
0.430
Above median 50 68 48 30 0.885
Below median 50 68 44 34
M2 density in islets + stroma 1.007
(0.994 - 1.021)
0.290
Above median 50 64 42 30 0.467
Below median 50 72 48 34
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macrophage forms determines the anti- or pro-tumor
effects of the macrophage population [11].
Heterogeneity of macrophages may account for part of
the controversies in regard to TAMs’ role in prognosis.
For example, Chen et al reported that TAMs are nega-
tively associated with survival in NSCLC patients [13].
Toomey et al found that there is no association between
macrophage number and prognosis of NSCLC [14]. On
the other hand, Welsh et al found that the macrophage
density in the tumor islets is positively associated with
patient’s survival [4]. Our previous study showed that
the macrophage density in the tumor islets is positively
associated with survival, whereas the macrophage den-
sity in the tumor stroma is negatively associated with
survival [10]. We hypothesized that assessment of the
M1 versus M2 macrophage density in the tumor islets
and stroma may provide new insights into understand-
ing the role of TAMs in prognosis of NSCLC.
In this study, we found that in 100 cases of non-small
cell lung cancer, the M2 macrophage is the predominant
form of TAMs, consisting of 70% of the overall macro-
phage population. In comparison between the long
survival and short survival groups of patients, there is
no significant difference with respect to the M2 macro-
phage densities in the tumor islets, stroma, or islets and
stroma. In contrast, the M1 macrophage densities in the
tumor islets, stroma, or islets and stroma are signifi-
cantly higher in the long survival group than in the
short survival group. These findings imply that the M1
macrophage density may be associated with patient’s
survival. Indeed, using the Spearman’s rank correlation
coefficient analysis, we confirmed that the M1 macro-
phage densities in the tumor islets, stroma, or islets and
stroma are positively associated with patient’s survival
time. Furthermore, using the median value of the M1
macrophage density as a cut-off point, patients with
above-the-median M1 macrophage density in the tumor
islets, stroma, or islets and stroma had significantly
higher cumulative survival rates, compared to patients
with below-the-median M1 macrophage density in a
univariate analysis. However, in a multivariate analysis,
only the M1 macrophage density in the tumor islets
remains as an independent predictor of patient’s survival
time. These results suggest that assessment of the M1
Figure 3 Kaplan-Meier survival curves. One hundred patients (N = 100) are divided into two groups with the macrophage densities above or
below the median value. P values are obtained in comparisons of the two groups through a univariate analysis using the log-rank test. [M1] and
[M2] represent the M1 macrophage density and M2 macrophage density, respectively.
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macrophage density in the tumor islets can be very
helpful in predicting survival time of patients with
NSCLC.
Our results are consistent with a recent report that
the M1 macrophage density in the tumor islets is posi-
tively associated with extended survival of NSCLC
patients [9]. What differs between the two studies is
that we do not observe any statistically significant differ-
ence in terms of the M2 macrophage densities between
the long survival and short survival groups, whereas the
other study [9] found an increase of the M2 macrophage
density in the tumor islets of the extended survival
group. Both studies used the same clone (10D6) of
mouse anti-human CD163 antigen monoclonal antibo-
dies and similar techniques to detect the M2 macro-
phage. We speculate that difference in patient
populations and evaluation protocols may be the main
reasons for the discrepancy. Nevertheless, these studies
suggest that immune responses, particularly infiltration
of the M1 macrophages into the tumor islets, may play
a crucial role in preventing progression of non-small
cell lung cancer. The putative biological mechanisms
may include direct effects of reactive oxygen/nitrogen
intermediates and TNFa released by the M1 macro-
phages in close proximity to the tumor cells, and/or
indirect effects through activation and recruitment of
cytotoxic T cells [15]. It is speculated that any pharma-
cological interventions to induce differentiation of the
M1 macrophages and/or to promote infiltration of the
M1 macrophages into the tumor islets would provide
therapeutic benefits to patients with non-small cell lung
cancer. Future studies are needed to confirm this
speculation.
The limitation of this study is that the markers used
are not very specific. Although CD68 has been widely
used to identify macrophages [9,16-18]], it has been
found in immature CD1a-positive dendritic cells [19,20].
HLA-DR has been found to be expressed in the periph-
eral lymphocytes [21] and CD163 is also expressed in
some dendritic cells [22]. Therefore, there is a possibility
that some cells as identified by these three markers are
not macrophages. Ideally, the cells should be stained
with multiple markers. However, multiple staining
would be technically challenging in handling the
archived paraffin-embedded tissues.
Conclusions
This study demonstrates that the tumor-associated
macrophages in non-small cell lung cancer contain two
distinct forms, a CD68+/HLA-DR+ M1 form and a
CD68+/CD163+ M2 form. The M1 and M2 macro-
phages consist of 30% and 70% of TAMs in NSCLC,
respectively. The M1 macrophage densities in the tumor
islets, stroma, or islets and stroma are significantly
higher in patients with an average of 5-year survival,
compared to patients with an average of 1-year survival.
The M1 macrophage density in the tumor islets is an
independent factor that can predict patient’s survival
time. The M2 macrophage density is not associated with
patient’s survival time.
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